Aileron Therapeutics Statistics
Total Valuation
ALRN has a market cap or net worth of $59.80 million. The enterprise value is $87.15 million.
Important Dates
The last earnings date was Thursday, November 14, 2024, after market close.
Earnings Date | Nov 14, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
ALRN has 21.67 million shares outstanding. The number of shares has increased by 201.87% in one year.
Current Share Class | 21.67M |
Shares Outstanding | 21.67M |
Shares Change (YoY) | +201.87% |
Shares Change (QoQ) | +8.80% |
Owned by Insiders (%) | 1.19% |
Owned by Institutions (%) | 19.48% |
Float | 19.42M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 1.19 |
P/TBV Ratio | n/a |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.30
Current Ratio | 3.30 |
Quick Ratio | 3.12 |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -54.95% and return on invested capital (ROIC) is -34.78%.
Return on Equity (ROE) | -54.95% |
Return on Assets (ROA) | -31.63% |
Return on Capital (ROIC) | -34.78% |
Revenue Per Employee | n/a |
Profits Per Employee | -$1.95M |
Employee Count | 15 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Dividends & Yields
ALRN does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -201.87% |
Shareholder Yield | -201.87% |
Earnings Yield | -48.90% |
FCF Yield | -46.61% |
Analyst Forecast
The average price target for ALRN is $19.00, which is 588.41% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $19.00 |
Price Target Difference | 588.41% |
Analyst Consensus | Strong Buy |
Analyst Count | 1 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | -25.20% |
Stock Forecasts Stock Splits
The last stock split was on November 11, 2022. It was a reverse split with a ratio of 0.05:1.
Last Split Date | Nov 11, 2022 |
Split Type | Reverse |
Split Ratio | 0.05:1 |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 1 |